About psyence biomedical ltd - PBM
Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on February 25, 2021 and is headquartered in Toronto, Canada.
PBM At a Glance
Psyence Biomedical Ltd.
121 Richmond Street West
Toronto, Ontario M5H 2K1
| Phone | 1-416-346-7764 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | 1.01M | |
| Sector | Health Technology | Employees | 12 | |
| Fiscal Year-end | 03 / 2026 | |||
| View SEC Filings |
PBM Valuation
| P/E Current | 0.446 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.685 |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.404 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.944 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PBM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | 84,315.833 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PBM Liquidity
| Current Ratio | 11.037 |
| Quick Ratio | 11.037 |
| Cash Ratio | 10.383 |
PBM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | 23.952 |
| Return on Equity | N/A |
| Return on Total Capital | 15.052 |
| Return on Invested Capital | N/A |
PBM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |